Avidination for RadionuclideTHerapy in Nonpalpable Breast Cancer - Trial NCT06390241
Access comprehensive clinical trial information for NCT06390241 through Pure Global AI's free database. This Phase 1 trial is sponsored by Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori and is currently Not yet recruiting. The study focuses on Breast Cancer. Target enrollment is 52 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Timeline & Enrollment
Phase 1
Jun 01, 2024
Jan 01, 2025
Primary Outcome
Safety of avidin-biotin-Dota-90Y,Safety of avidin-biotin-Dota-90Y,Anti-tumor activity of avidin-biotin-Dota-90Y
Summary
This is an interventional, open-label, non comparative phase 2 trial enrolling patients with
 nonpalpable breast cancer
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06390241
Non-Device Trial